+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 6Months - 9Months
All Genders
Healthy Volunteers
ID07578298

Passive Immunisation Using RSV-Specific Monoclonal Antibody Nirsevimab to Prevent RSV Infections in Aboriginal and Torres Strait Islander Children in Northern Territory

Led by Menzies School of Health Research · Updated on 2026-10-07

1000

Participants Needed

1

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

Respiratory syncytial virus RSV causes serious respiratory illness and hospitalizations in young children, especially among Aboriginal and Torres Strait Islander children in Australias Northern Territory. This trial evaluates whether giving a single dose of the RSV-specific monoclonal antibody nirsevimab at around 6 months old can protect these children against RSV infections during their first two years of life. The study uses a pragmatic, randomized controlled design to assess this prevention strategy under real-world conditions. Participants are randomly assigned to receive either one dose of nirsevimab injected into the muscle or standard care without the monoclonal antibody. The dose of nirsevimab is based on the childs weight and given once between 6 months old plus 90 days. Follow-up is mainly passive, using electronic medical records and public health notifications to track RSV infections and hospital visits related to RSV and respiratory illness over 6 and 12 months. The trial also includes an economic evaluation of the interventions cost-effectiveness. At enrollment, basic health and immunization data are collected to confirm eligibility and describe the study population. A brief follow-up call about a week after dosing checks early safety. No extra study visits are required beyond routine healthcare. Researchers will measure RSV infection rates as the primary outcome, along with hospital attendances and admissions related to RSV and respiratory conditions. Passive surveillance will continue up to 12 months after dosing to assess these outcomes, while participants continue their usual healthcare.

CONDITIONS

Brief Title

THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness

Research Team

B

Bianca Middleton

S

Sarah Gallagher

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here